Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations. (IDENTIFY)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this trial is to compare the evolution of patients receiving first line treatment for locally advanced or metastatic lung cancer, taking into account if they were requested or not the EGFR mutation test as part of the diagnosis and treatment strategy. There is no assignment to any particular therapeutic strategy.
Condition or disease
Stage IIIB/IVNon-Small Cell Lung Cancer
Study of cases and controls on diagnosis and treatment strategies in patients with NSCLC with or without EGFR mutations.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients will be recruited from specialized sites; all the participating investigators will be oncologists.
Patients with confirmed diagnosis of lung adenocarcinoma, stage IIIb/IV.
Patients under 1st line treatment against lung adenocarcinoma.
Patients not having the information required by the protocol.